About Leap Therapeutics (NASDAQ:LPTX)
Leap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer, cholangiocarcinoma, non-small cell lung cancer, and other tumor types, such as pancreatic, gastric, liver, head and neck, uterine, and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. .
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LPTX
CUSIPN/A
Phone617-714-0360
Debt
Debt-to-Equity RatioN/A
Current Ratio4.55%
Quick Ratio4.55%
Price-To-Earnings
Trailing P/E Ratio-2.15
Forward P/E Ratio-3.00
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.90 per share
Price / Book7.90
Profitability
EPS (Most Recent Fiscal Year)($3.31)
Net Income$-29,720,000.00
Net MarginsN/A
Return on Equity-182.37%
Return on Assets-121.19%
Miscellaneous
Employees22
Outstanding Shares14,500,000
Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions
What is Leap Therapeutics' stock symbol?
Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."
How were Leap Therapeutics' earnings last quarter?
Leap Therapeutics (NASDAQ:LPTX) issued its earnings results on Friday, February, 23rd. The company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.77) by $0.12. View Leap Therapeutics' Earnings History.
What price target have analysts set for LPTX?
1 equities research analysts have issued twelve-month price objectives for Leap Therapeutics' shares. Their forecasts range from $12.50 to $12.50. On average, they anticipate Leap Therapeutics' stock price to reach $12.50 in the next twelve months. View Analyst Ratings for Leap Therapeutics.
What are Wall Street analysts saying about Leap Therapeutics stock?
Here are some recent quotes from research analysts about Leap Therapeutics stock:
- 1. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Initial DKN-01 Results Show Promise; Anti- GITR Combines Well With Chemo; Reiterate Buy Preclinical and clinical results highlights the effects of DKN-01 on the immune system. On April 16, Leap presented new results at the 2018 American Association for Cancer Research (AACR) Annual Conference that highlight the immunomodulatory effect of DKN-01 in preclinical tumor models. According to the latest results, DKN-01 is able to significantly alter the makeup of the tumor microenvironment (Exhibit 1), attract immune cells by inducing Cxcl10 expression (Exhibit 2), and improve the efficacy of PD-1 checkpoint inhibition (Exhibit 3)." (4/12/2018)
- 2. According to Zacks Investment Research, "Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. " (1/23/2018)
Who are some of Leap Therapeutics' key competitors?
Some companies that are related to Leap Therapeutics include VBI Vaccines (VBIV), Menlo Therapeutics (MNLO), Ra Pharmaceuticals (RARX), POXEL (PXXLF), Xoma (XOMA), Marinus Pharmaceuticals (MRNS), Summit Therapeutics (SMMT), Nabriva Therapeutics (NBRV), Scpharmaceuticals (SCPH), Teligent (TLGT), Protagonist Therapeutics (PTGX), Zafgen (ZFGN), Evolus (EOLS), Spero Therapeutics (SPRO), Spring Bank Pharmaceuticals (SBPH), Avid Bioservices (CDMO), Kamada (KMDA) and Proteostasis Therapeutics (PTI).
Has Leap Therapeutics been receiving favorable news coverage?
Headlines about LPTX stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Leap Therapeutics earned a news impact score of 0.05 on Accern's scale. They also gave press coverage about the company an impact score of 46.85 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Leap Therapeutics?
Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Leap Therapeutics' stock price today?
One share of LPTX stock can currently be purchased for approximately $7.11.
How big of a company is Leap Therapeutics?
Leap Therapeutics has a market capitalization of $103.10 million. The company earns $-29,720,000.00 in net income (profit) each year or ($3.31) on an earnings per share basis. Leap Therapeutics employs 22 workers across the globe.
How can I contact Leap Therapeutics?
Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.
MarketBeat Community Rating for Leap Therapeutics (LPTX)
MarketBeat's community ratings are surveys of what our community members think about Leap Therapeutics and other stocks. Vote "Outperform" if you believe LPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Leap Therapeutics (NASDAQ:LPTX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Leap Therapeutics (NASDAQ LPTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 58.70%
Institutional Ownership Percentage: 2.77%
Leap Therapeutics (NASDAQ LPTX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/14/2017 | Augustine Lawlor | COO | Buy | 1,057,769 | $6.09 | $6,441,813.21 | |  |
(Data available from 1/1/2013 forward)
Leap Therapeutics (NASDAQ LPTX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | CLDX Disappoints Investors, ASNS Awaits Data In 2H18, BPMC Fails To Make A Mark
www.nasdaq.com - April 17 at 9:07 AM |
 | Leap Therapeutics (LPTX) Expected to Post Earnings of -$0.51 Per Share
www.americanbankingnews.com - April 14 at 1:09 AM |
| HC Wainwright Initiates Coverage on Leap Therapeutics (LPTX)
www.americanbankingnews.com - April 12 at 10:51 AM |
| Vanda Pharmaceuticals (VNDA) versus Leap Therapeutics (LPTX) Head to Head Contrast
www.americanbankingnews.com - April 9 at 11:13 AM |
| Leap Therapeutics (LPTX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 7 at 10:55 AM |
| Zacks: Leap Therapeutics Inc (LPTX) Given $15.50 Consensus Target Price by Brokerages
www.americanbankingnews.com - April 7 at 9:55 AM |
| Leap Therapeutics (LPTX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - March 30 at 11:10 PM |
| Leap Therapeutics (LPTX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - March 30 at 8:24 PM |
 | Leap Therapeutics (LPTX) Presents At Needham and Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 5:03 PM |
| Leap raises $16.1M in equity offering
seekingalpha.com - March 27 at 4:52 PM |
 | Leap Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - March 27 at 4:52 PM |
| Leap Therapeutics (LPTX) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - March 26 at 10:24 PM |
| Leap Therapeutics prices public offering of common stock
seekingalpha.com - March 24 at 4:55 PM |
| Leap Therapeutics (LPTX) Upgraded at ValuEngine
www.americanbankingnews.com - March 23 at 10:46 PM |
| Leap Therapeutics Announces Pricing of $14 Million Public Offering of Common Stock
finance.yahoo.com - March 23 at 5:11 PM |
| Zacks: Analysts Set $15.50 Target Price for Leap Therapeutics Inc (LPTX)
www.americanbankingnews.com - March 23 at 1:16 AM |
| Leap Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 22 at 5:10 PM |
| Leap Therapeutics to Present at the 2018 Needham & Company 17th Annual Healthcare Conference
finance.yahoo.com - March 21 at 9:41 AM |
 | Leap Therapeutics (LPTX) Provides DKN-01 Program Update and Announces Scientific Presentations at AACR
www.streetinsider.com - March 15 at 8:44 AM |
| Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting
finance.yahoo.com - March 15 at 8:44 AM |
| Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting
finance.yahoo.com - March 14 at 6:30 PM |
| Leap Therapeutics Inc (LPTX) Expected to Announce Earnings of -$0.51 Per Share
www.americanbankingnews.com - March 10 at 9:20 PM |
| Zacks: Leap Therapeutics Inc (LPTX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 8 at 9:29 PM |
| Zacks: Brokerages Set $15.50 Price Target for Leap Therapeutics Inc (LPTX)
www.americanbankingnews.com - February 27 at 1:24 PM |
| Zacks: Analysts Anticipate Leap Therapeutics Inc (LPTX) to Post -$0.77 Earnings Per Share
www.americanbankingnews.com - February 22 at 3:14 AM |
| Analysts Anticipate Leap Therapeutics Inc (LPTX) to Post ($0.77) EPS
www.americanbankingnews.com - February 21 at 12:05 PM |
| Analysts Anticipate Leap Therapeutics Inc (LPTX) to Post ($0.77) Earnings Per Share
www.americanbankingnews.com - February 6 at 3:34 PM |
| Leap Therapeutics to Present at the 20th Annual BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 9:32 AM |
| Zacks: Leap Therapeutics Inc (LPTX) Given $15.50 Average Price Target by Brokerages
www.americanbankingnews.com - February 2 at 7:24 PM |
| Leap Therapeutics (LPTX) and Aeglea Bio Therapeutics (AGLE) Head-To-Head Comparison
www.americanbankingnews.com - February 2 at 1:18 AM |
| Leap Therapeutics (LPTX) and The Competition Head to Head Analysis
www.americanbankingnews.com - January 24 at 1:38 PM |
| Leap Therapeutics (LPTX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 21 at 12:32 AM |
| Brokerages Anticipate Leap Therapeutics Inc (LPTX) to Post -$0.77 EPS
www.americanbankingnews.com - January 19 at 5:28 AM |
| Brokerages Set $15.50 Price Target for Leap Therapeutics Inc (LPTX)
www.americanbankingnews.com - January 18 at 3:06 AM |
| Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial
finance.yahoo.com - January 16 at 9:23 AM |
| Head-To-Head Analysis: Leap Therapeutics (LPTX) & Its Rivals
www.americanbankingnews.com - January 15 at 9:16 PM |
| Leap Therapeutics (LPTX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 14 at 7:27 PM |
| Leap Therapeutics Inc (LPTX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 14 at 3:38 PM |
| Leap Therapeutics (LPTX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - January 9 at 6:08 AM |
| Leap Therapeutics (LPTX) & The Competition Head to Head Review
www.americanbankingnews.com - January 2 at 9:14 PM |
| Contrasting Leap Therapeutics (LPTX) & Its Peers
www.americanbankingnews.com - December 31 at 3:28 AM |
| Zacks: Leap Therapeutics Inc (LPTX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 28 at 1:10 AM |
| Form DEF 14A LEAP THERAPEUTICS, INC. For: Jan 12
www.streetinsider.com - December 19 at 5:29 PM |
| Zacks: Leap Therapeutics, Inc. (LPTX) Given $15.50 Average Price Target by Analysts
www.americanbankingnews.com - November 27 at 10:06 AM |
| Leap Therapeutics Announces $18 Million Private Placement Offering
finance.yahoo.com - November 17 at 2:10 PM |
| What’s Installed For Leap Therapeutics Inc (LPTX)?
finance.yahoo.com - November 17 at 2:10 PM |
| Leap Therapeutics, Inc. (LPTX) COO Purchases $6,441,813.21 in Stock
www.americanbankingnews.com - November 16 at 4:22 PM |
| Leap Therapeutics, Inc. (LPTX) Issues Earnings Results, Misses Estimates By $0.11 EPS
www.americanbankingnews.com - November 14 at 11:24 AM |
| Leap Therapeutics Reports Third Quarter 2017 Financial Results and Announces First Patient Dosed with DKN-01 and KEYTRUDA® (pembrolizumab) in Esophagogastric Cancer Trial
finance.yahoo.com - November 13 at 5:12 PM |
| Zacks: Analysts Set $15.50 Price Target for Leap Therapeutics, Inc. (LPTX)
www.americanbankingnews.com - November 12 at 7:38 PM |
Leap Therapeutics (NASDAQ:LPTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Leap Therapeutics (NASDAQ:LPTX) Income Statement, Balance Sheet and Cash Flow Statement
Leap Therapeutics (NASDAQ LPTX) Stock Chart for Monday, April, 23, 2018
Loading chart…
